Literature DB >> 8396401

Human submandibular saliva aggregates HIV.

D Malamud1, C Davis, P Berthold, E Roth, H Friedman.   

Abstract

Incubation of HIV with human whole, parotid, or submandibular saliva leads to a decrease in viral infectivity in Sup-T1 cells. The effect is most pronounced with submandibular saliva. Inhibition is seen within 2 min, and increases with time. There is little inhibition seen after incubation of saliva with HSV, and no effect with adenovirus, suggested that there is some viral specificity. Electron microscopic studies revealed that HIV-saliva aggregates are trapped in 0.45-microns pore size nitrocellulose filters. If these inhibitory effects are manifest in vivo, this could account for the low level of virus detected in oral secretions.

Entities:  

Mesh:

Year:  1993        PMID: 8396401     DOI: 10.1089/aid.1993.9.633

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  19 in total

Review 1.  The significance of oral health in HIV disease.

Authors:  I L Chapple; J Hamburger
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

Review 2.  Antiviral activities in human saliva.

Authors:  D Malamud; W R Abrams; C A Barber; D Weissman; M Rehtanz; E Golub
Journal:  Adv Dent Res       Date:  2011-04

3.  Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Authors:  Jessica S Thomas; Nedra Lacour; Pamela A Kozlowski; Steve Nelson; Gregory J Bagby; Angela M Amedee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

Review 4.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

5.  Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.

Authors:  A A Baqui; T F Meiller; W A Falkler
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

6.  Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.

Authors:  William Domm; Lauren Brooks; Hung Li Chung; Changyong Feng; William J Bowers; Gene Watson; James L McGrath; Stephen Dewhurst
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

Review 7.  The oral mucosa immune environment and oral transmission of HIV/SIV.

Authors:  Lianna F Wood; Ann Chahroudi; Hui-Ling Chen; Heather B Jaspan; Donald L Sodora
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

8.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.

Authors:  T B McNeely; M Dealy; D J Dripps; J M Orenstein; S P Eisenberg; S M Wahl
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

9.  Quantitative analysis of differentially expressed saliva proteins in human immunodeficiency virus type 1 (HIV-1) infected individuals.

Authors:  Nawei Zhang; Zhenyu Zhang; Shan Feng; Qingtao Wang; Daniel Malamud; Haiteng Deng
Journal:  Anal Chim Acta       Date:  2013-03-01       Impact factor: 6.558

10.  HIV envelope binding by macrophage-expressed gp340 promotes HIV-1 infection.

Authors:  Georgetta Cannon; Yanjie Yi; Houping Ni; Earl Stoddard; David A Scales; Donald I Van Ryk; Irwin Chaiken; Daniel Malamud; Drew Weissman
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.